Camlin Fine Sciences Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Ashish Dandekar
Geschäftsführender
₹28.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 54.61% |
| Amtszeit als Geschäftsführer | 19.3yrs |
| Eigentum des Geschäftsführers | 10.3% |
| Durchschnittliche Amtszeit des Managements | 4.7yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.7yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).Narrativ-Update • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narrativ-Update • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrativ-Update • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrativ-Update • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrativ-Update • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrativ-Update • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).Narrativ-Update • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.Narrativ-Update • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.Narrativ-Update • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).Narrativ-Update • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.Narrativ-Update • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Neues Narrativ • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -₹141m |
| Sep 30 2025 | n/a | n/a | ₹187m |
| Jun 30 2025 | n/a | n/a | ₹825m |
| Mar 31 2025 | ₹28m | ₹15m | ₹685m |
| Dec 31 2024 | n/a | n/a | -₹2b |
| Sep 30 2024 | n/a | n/a | -₹2b |
| Jun 30 2024 | n/a | n/a | -₹1b |
| Mar 31 2024 | ₹29m | ₹15m | ₹651m |
| Dec 31 2023 | n/a | n/a | -₹8m |
| Sep 30 2023 | n/a | n/a | ₹350m |
| Jun 30 2023 | n/a | n/a | ₹674m |
| Mar 31 2023 | ₹26m | ₹14m | ₹577m |
| Dec 31 2022 | n/a | n/a | ₹581m |
| Sep 30 2022 | n/a | n/a | ₹628m |
| Jun 30 2022 | n/a | n/a | ₹442m |
| Mar 31 2022 | ₹20m | ₹12m | ₹650m |
| Dec 31 2021 | n/a | n/a | ₹598m |
| Sep 30 2021 | n/a | n/a | ₹465m |
| Jun 30 2021 | n/a | n/a | ₹579m |
| Mar 31 2021 | ₹18m | ₹11m | ₹510m |
| Dec 31 2020 | n/a | n/a | ₹394m |
| Sep 30 2020 | n/a | n/a | ₹291m |
| Jun 30 2020 | n/a | n/a | ₹302m |
| Mar 31 2020 | ₹18m | ₹11m | ₹303m |
Vergütung im Vergleich zum Markt: AshishDie Gesamtvergütung ($USD292.85K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD174.21K).
Entschädigung vs. Einkommen: AshishDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Ashish Dandekar (61 yo)
19.3yrs
Amtszeit
₹28,216,000
Vergütung
Mr. Ashish Subhash Dandekar serves as the Chairman of Board at Camlin Fine Sciences Limited since June 17, 2021. He has been the Managing Director of Camlin Fine Sciences Limited (formerly known as Camlin...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & MD | no data | ₹28.22m | 10.34% ₹ 2.4b | |
| MD & Director | 4.9yrs | ₹24.56m | 1.88% ₹ 442.1m | |
| Executive Director of Technical & Executive Director | no data | ₹11.98m | 0.10% ₹ 23.9m | |
| Chief Financial Officer | 9.3yrs | keine Daten | keine Daten | |
| Chief Operating Officer | 2.4yrs | keine Daten | keine Daten | |
| Company Secretary | 4.5yrs | ₹1.39m | keine Daten | |
| Global Head of IT | no data | keine Daten | keine Daten | |
| Management Consultant | no data | keine Daten | keine Daten |
4.7yrs
Durchschnittliche Betriebszugehörigkeit
58.5yo
Durchschnittliches Alter
Erfahrenes Management: 532834Das Führungsteam des Unternehmens gilt als erfahren (4.7 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman & MD | 19.3yrs | ₹28.22m | 10.34% ₹ 2.4b | |
| MD & Director | 11.8yrs | ₹24.56m | 1.88% ₹ 442.1m | |
| Executive Director of Technical & Executive Director | 7.9yrs | ₹11.98m | 0.10% ₹ 23.9m | |
| Independent Director | 1.3yrs | ₹600.00k | 0.068% ₹ 16.0m | |
| Non-Executive Non-Independent Director | 5.8yrs | keine Daten | keine Daten | |
| Non-Executive Independent Director | 4.6yrs | ₹2.45m | keine Daten | |
| Non-Executive Non-Independent Director | 8.6yrs | ₹700.00k | 1.57% ₹ 369.9m | |
| Independent Director | 5.7yrs | ₹2.46m | keine Daten | |
| Independent Non-Executive Director | 5.4yrs | ₹2.64m | 0.0031% ₹ 734.5k | |
| Independent Director | 6.8yrs | ₹2.18m | keine Daten | |
| Independent Director | 1.2yrs | ₹125.00k | keine Daten | |
| Non-Executive Non-Independent Director | 1.2yrs | keine Daten | keine Daten |
5.7yrs
Durchschnittliche Betriebszugehörigkeit
59.5yo
Durchschnittliches Alter
Erfahrener Vorstand: 532834Die Vorstandsmitglieder gelten als erfahren (5.7 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 08:00 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Camlin Fine Sciences Limited wird von 9 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |